Skip to search formSkip to main contentSkip to account menu

AT 101

Known as: AT-101, AT101 cpd 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

Gossypolgossypol acetic acid
l-gossypol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets
Abstract Platelet lifespan is regulated by intrinsic apoptosis. Platelet apoptosis can be triggered by BH3 mimetics that inhibit… 
2019
2019
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101
Osteosarcoma (OS) is the most common primary malignant bone tumor and mainly affects children and adolescents. The OS five-year… 
2015
2015
Correction: BNIP3 Regulates AT101 [(-)-Gossypol] Induced Death in Malignant Peripheral Nerve Sheath Tumor Cells
There is an error in Fig 1. In Fig 1C, the y-axis should read: “Percentage of ethidium homodimer-1 positive dead cells.” Please… 
2012
2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
2012
2012
Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels
PurposeTumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and has been shown to… 
2010
2010
Re: Kim N. Chi, Anders Bjartell, David Dearnaley, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56:594-605.
2010
2010
Phase Ib dose-escalation study of MetMAb, a monovalent antagonist antibody to the receptor MET, in combination with bevacizumab in patients with locally advanced or metastatic solid tumors.
e13050 Background: Crosstalk between the Met and vascular endothelial growth factor (VEGF) pathways may be important during… 
2009
2009
An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC).
5062 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in CRPC and contribute to resistance to therapy. The oral… 
2008
2008
An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with hormone refractory prostate cancer (HRPC)
16043 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in HRPC and contribute to resistance to therapy. The oral… 
2008
2008
Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy
19004 Background: Antiapoptotic members of the Bcl-2 protein family are expressed in the tumor tissue of the majority of patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)